Cencora, Inc. (NYSE:COR) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Cencora, Inc. (NYSE:COR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $289.09.

A number of equities analysts have commented on COR shares. Morgan Stanley set a $288.00 target price on Cencora in a research note on Tuesday, April 15th. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Wells Fargo & Company lifted their target price on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Bank of America boosted their price objective on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th.

Insider Activity

In other news, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This trade represents a 21.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock worth $13,580,967 over the last 90 days. 10.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cencora

Several hedge funds have recently modified their holdings of COR. Passumpsic Savings Bank lifted its holdings in shares of Cencora by 4.9% during the third quarter. Passumpsic Savings Bank now owns 6,464 shares of the company's stock valued at $1,455,000 after purchasing an additional 304 shares during the last quarter. Virtu Financial LLC lifted its holdings in shares of Cencora by 112.2% during the third quarter. Virtu Financial LLC now owns 10,227 shares of the company's stock valued at $2,302,000 after purchasing an additional 5,407 shares during the last quarter. World Investment Advisors LLC purchased a new stake in shares of Cencora during the third quarter valued at $4,072,000. Arvest Bank Trust Division purchased a new stake in shares of Cencora during the third quarter valued at $218,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Cencora during the third quarter valued at $566,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 0.8 %

NYSE:COR traded up $2.37 during mid-day trading on Thursday, reaching $290.12. The stock had a trading volume of 1,250,227 shares, compared to its average volume of 1,523,457. The company has a market capitalization of $56.26 billion, a price-to-earnings ratio of 41.27, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. Cencora has a 1-year low of $214.77 and a 1-year high of $296.65. The stock's 50 day simple moving average is $269.87 and its two-hundred day simple moving average is $250.27. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities analysts anticipate that Cencora will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.76%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.